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Background: Heart failure is a multifactorial disease associated with staggeringly high morbidity and motility.
Recently, alterations of multiple metabolites have been implicated in heart failure; however, the lack of an effective
technology platform to assess these metabolites has limited our understanding on how they contribute to this
disease phenotype. We have successfully developed a new workflow combining specific sample preparation with
tandem mass spectrometry that enables us to extract most of the targeted metabolites. 19 metabolites were
chosen ascribing to their biological relevance to heart failure, including extracellular matrix remodeling,
inflammation, insulin resistance, renal dysfunction, and cardioprotection against ischemic injury.
Results: In this report, we systematically engineered, optimized and refined a protocol applicable to human plasma
samples; this study contributes to the methodology development with respect to deproteinization, incubation,
reconstitution, and detection with mass spectrometry. The deproteinization step was optimized with 20%
methanol/ethanol at a plasma:solvent ratio of 1:3. Subsequently, an incubation step was implemented which
remarkably enhanced the metabolite signals and the number of metabolite peaks detected by mass spectrometry
in both positive and negative modes. With respect to the step of reconstitution, 0.1% formic acid was designated
as the reconstitution solvent vs. 6.5 mM ammonium bicarbonate, based on the comparable number of metabolite
peaks detected in both solvents, and yet the signal detected in the former was higher. By adapting this finalized
protocol, we were able to retrieve 13 out of 19 targeted metabolites from human plasma.
Conclusions: We have successfully devised a simple albeit effective workflow for the targeted plasma metabolites
relevant to human heart failure. This will be employed in tandem with high throughput liquid chromatography
mass spectrometry platform to validate and characterize these potential metabolic biomarkers for diagnostic and
therapeutic development of heart failure patients.
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Heart failure refers to the cardiac malfunction in pumping
sufficient amount of blood to meet the metabolic demand
of the body. To date, there are over 6.6 million heart failure
patients in the U.S. [1]. In spite of the integration of vari-
ous medical regiments, such as ACE-inhibitors, β-blockers,
the morbidity and mortality of heart failure patients remain
staggeringly high, in which more than 80% of heart failure
patients have to be hospitalized [2]; 50% of which die* Correspondence: PPing@mednet.ucla.edu
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reproduction in any medium, provided the orwithin 5 years of the diagnosis [3,4]. This dramatic situ-
ation places an enormous burden on both the health care
sector as well as the economy. Furthermore, the existing
screening tests adapted to examine various classic cardio-
vascular risk factors, such as hypertension, hyperlipidemia,
smoking, and diabetes…etc. cannot fully delineate and pre-
cisely evaluate the inter-individual variation [5]. This limi-
tation urges an expanded and comprehensive diagnostic
platform to achieve an accurate assessment of the disease
stage, as well as the subsequent complementary treatments
for heart failure patients.
Heart failure is a multifactorial and multigenic disease,
in which several biological processes have shown to be
critical, including extracellular matrix remodeling, energytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Human plasma 
Step 1: Deproteinization 
Metabolite identification by mass  spectrometry
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Figure 1 An overview of existing workflow for sample
preparation in the studies of human plasma metabolomics.
Human plasma is first deproteinized with organic solvent, in which
proteins are precipitated (step 1). The metabolites in the supernatant
are then subjected to lyophilization (step 2) and reconstitution for
subsequent mass spectrometric analyses (step 3).
Chan et al. Clinical Proteomics 2013, 10:7 Page 2 of 9
http://www.clinicalproteomicsjournal.com/content/10/1/7metabolism, and inflammation. In the aspect of extracellu-
lar matrix remodeling, ischemic heart failure is character-
ized by massive fibrous tissue formation at the site of
myocardial infarction [6,7] and its vicinity. This uncontrol-
lable extracellular matrix accumulation leads to myocardial
stiffness, and hence the cardiac contractility is impaired
[8-13]. In the aspect of energy metabolism, malfunction
was reported in heart failure patients, whom encountered
severe energy deprivation, accompanied by muscular fa-
tigue and low exercise intolerance [14-18]. In the context
of myocardial inflammation, its pathophysiological
relevance to heart failure has been recognized since
1669 [19]. Chronic heart failure patients displayed epi-
sodes of systemic inflammation, as evident by the
increased circulating cytokines [20,21]. In view of the
aforementioned pathological phenotypes of heart fail-
ure and their relevant biology in metabolism, we
designed and implemented a metabolomic approach in
an effort to profile metabolites, such as lipids, amino
acids, and sugars, whose functions are to maintain and
orchestrate the normal biological processes and pheno-
type of an organism [22-31].
Metabolomics has emerged as an effective technical
strategy for the development of efficient diagnostic markers
and therapeutic interventions [32-34]. Previously, we have
adapted an approach combining proteomic and nuclear
magnetic resonance spectroscopy-based metabolomics to
identify key proteins and cardiac energy metabolites in-
volved in cardioprotection during ischemia/reperfusion in-
jury [35]. In this investigation, we initiated an effort to
establish a mass spectrometry-based metabolomic analyt-
ical platform to characterize and to validate potential meta-
bolic markers in heart failure, particularly in plasma due
to its less-invasiveness nature compared to biopsy [36];
also its circulating nature enables us to obtain a temporal
physiologic status of the patients [37]. 19 metabolites
were chosen based on their demonstrated functions in the
relevant biological processes to heart failure, specifically
participating in the regulation of extracellular matrix re-
modeling [38], energy metabolism [39-41], inflammation
[42], insulin resistance [43], renal dysfunction [44], and
cardioprotection [45].
Despite the development of new technologies, to date,
no protocols are available to extract all targeted metabo-
lites in a singular sample preparation due to their broad
dynamic range and their diverse chemical properties.
With the limited sample volume from the patients, we
encountered technical challenges to profile these metab-
olites in parallel in clinical studies. It is pivotal to devise
a simple yet effective workflow that enables us to extract
most, if not all, of the targeted metabolites of interest.
Accordingly, we organized a focused effort in this study
to develop and to optimize a platform enabling the
characterization of multiple metabolites in one singleanalysis. Prior to proceeding with the clinical sample ana-
lysis, it is crucial to ensure the efficiency of the workflow
and to resolve any technical shortfalls. Therefore, we sys-
tematically engineered, optimized and refined a protocol
applicable to human plasma.
Results and discussion
The sample preparation workflow was adjusted and re-
fined in the levels of deproteinization, incubation, and re-
constitution; the general pipeline is illustrated in Figure 1.
In brief, sample is first deproteinized with organic solvent,
in which the proteins are precipitated, while the metabo-
lites remain in the supernatant. After which, the metabo-
lites in the supernatant are subjected to lyophilization.
The pellet as result is reconstituted in a solvent that is sus-
ceptible to the downstream analytical platform of choice. In
this report, we systematically optimized and validated each
of these steps, and have successfully established a finalized
protocol which enabled us to retrieve 13 out of 19 of our
targeted metabolites, as identified by mass spectrometry.
Optimization of deproteinization
Deproteinization is a crucial step that significantly impacts
the yield and types of metabolites to be extracted. Conven-
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Figure 2 Optimization of deproteinization. (a) In the step of monophasic deproteinization, two samples containing either plasma:solvent ratios of
1:3 or 1:9 were examined. In the condition of a 1:3 ratio, 300 μL of either methanol or ethanol was added to 100 μL of plasma; whereas in the setting
of a 1:9 ratio, 900 μL of methanol or ethanol was added to 100 μL of plasma. In the aspect of biphasic deproteinization, a two-step solvent addition
was introduced, starting with an addition of 100 μL chloroform with 200 μL of either methanol or ethanol to 200 μL of plasma, followed by an
addition of 400 μL 50% chloroform/H2O. Metabolites extracted via both mono- and biphasic methods were subjected to a 1-minute vortexing, and a
20-minute incubation on ice. After centrifugation, the metabolites in the supernatants were subsequently lyophilized at 45°C for 2 hours. (b) To further
optimize the step of monophasic deproteinization, various combinations of methanol/ethanol were prepared, and added to the plasma at a ratio of
either 1:3 or 1:9 (plasma:solvent).
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adapted because of its simplicity, in which a certain pro-
portion of organic solvent is added to the sample in a sin-
gle step [46,47]. To assess the efficiency of the two
extraction methods, four sets of plasma samples were pre-
pared. In monophasic extraction, ethanol or methanol was
added at a ratio of 1:3 or 1:9 (plasma:solvent), respectively.
In biphasic extraction, chloroform with either methanol or
ethanol was added; followed by 50% chloroform. After cen-
trifugation, the hydrophilic and hydrophobic metabolitesTable 1 Targeted human plasma metabolites identified in mo
Metabolite name Accesion # Monophasic
1:3 Methanol 1:3 Ethanol 1:9 Me




Uric acid HMDB00289 x
L-Arginine HMDB00517 x
Dodecanoic acid HMDB00638 x x
Palmitatic acid HMDB00220 x x x
Linoleatic acid HMDB00673 x x x
Stearic acid HMDB00827 x x xwere separated and collected (Figure 2a). In Table 1 and in
Additional file 1, the monophasic approach offered the
identification of a greater number of metabolites. There-
fore, we elected the monophasic deproteinization for our
study. As illustrated in Table 1, extraction of plasma sam-
ples by either 100% of methanol or 100% of ethanol gener-
ated comparable panel of metabolites. To systematically
refine the monophasic deproteinization that best suitable
for our targeted metabolites, different combinations of
methanol/ethanol (100%/0%, 80%/20%, 50%/50%, 20%/nophasic and biphasic deproteinizations
Biphasic

































Hexanoic acid HMDB00535 x x x x x x x




HMDB00725 x x x x
Creatine HMDB00064 x x x
L-Malate HMDB00156 x x x x












Dodecanoic acid HMDB00638 x x x x x x x x
Palmitatic acid HMDB00220 x x x x x x x x
Linoleatic acid HMDB00673 x x x x x x
Trans-Vaccenic
acid
HMDB03231 x x x x x
Stearic acid HMDB00827 x x x x x x x x




















Positive mode Negative mode 
Incubation 
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Figure 3 Implementation of an incubation step. (a) In the positive mode, the signal detected without an incubation step was 1.23E5. (b) This
signal was remarkably increased to 6.18E5 with an additional 4 peaks detected amid the incorporation of an incubation step. (c) In the negative
mode, the signal detected without the incubation step was 1.17E4. (d) This signal was enhanced to 2.29E4 with an additional 88 peaks detected
amid the implementation of an incubation step.
a
b
6.5mM Ammonium bicarbonate 
0.1% Formic acid 
Figure 4 Selection of a reconstitution solvent. (a) In the setting of 6.5 mM ammonium bicarbonate, the signal intensity was recorded as
3.49E3. (b) In the setting of 0.1% formic acid, the signal was enhanced to 2.29E4, with an additional 108 peaks detected. Therefore, 0.1% formic
acid was elected as the reconstitution solvent.
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to the plasma sample at a ratio of plasma:solvent vol-
ume either 1:3 or 1:9 (Figure 2b). As summarized in
Table 2 and in Additional file 2, maximum number of
targeted metabolites were identified via the extraction
step containing 20% methanol/ethanol with a plasma:
solvent ratio of 1:3.
The implementation of an incubation step improves the
metabolite yield
According to the generic metabolite preparation protocol,
once the sample is deproteinized with organic solvent,
such as methanol, it will subsequently be subjected to
lyophilization. We examined if an additional 20-minute in-
cubation step on ice before lyophilization would enhance
the metabolite yield. In this regard, two sets of plasma
samples were prepared and deproteinized with methanol
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Figure 5 Our recommended workflow for sample preparation
in the studies of targeted human plasma metabolites. 300 μL of
human plasma was first deproteinized by 900 μL of 20% methanol/
ethanol (step 1); then was incubated on ice for 20 minutes (step 2).
After which, the metabolites in the supernatant were obtained and
lyophilized at 45°C for 2 hours (step 3). The resulting pellet was
subsequently reconstituted with 300 μL of 0.1% formic acid for mass
spectrometric analyses (step 4).was directly subjected to lyophilization; whereas the other
was allowed to incubate on ice for 20 minutes prior to
lyophilization. Metabolites derived from both sets were
then reconstituted in 0.1% formic acid/50% methanol and
subjected to a static nanoelectrospray ionization coupled
to an LTQ orbitrap XL hybrid fourier transform mass
spectrometer (FTMS). Mass spectra were acquired in both
positive and negative modes. In the additional step with a
20-minute incubation on ice, there was a 5-fold increase
in signal intensity which led to an additional 4 peaks
detected in the positive mode; whereas in the negative
mode, there was a 2-fold increase in signal which resulted
the detection of an additional 88 peaks (Figure 3).Selection of a reconstitution solvent
Previous study by Evans and colleagues reported that
0.1% formic acid favored formation of the positive ions,
but suppressed the negative ions [48]. In this regard, am-
monium bicarbonate was recommended as the reconsti-
tution solvent in negative mode. Nonetheless, adapting
two different reconstitution solvent involves an add-
itional partition step to divide the plasma sample equally
into two portions: one reconstituted in 0.1% formic acid
for the positive mode; the other in ammonium bicarbon-
ate for the negative mode. This extra partition step may
introduce downstream quantitative variation due to the
inevitable experimental error. Furthermore, during liquid
chromatography-tandem mass spectrometry (LC-MS/MS)
analysis, two different sets of LC buffer have to be pre-
pared for both positive and negative modes; therefore an
additional conditioning time is required upon switching
the buffers. As a consequence, this process will attenuate
the high throughput capability of LC-MS/MS analysis.
To evaluate the outcome of adapting ammonium bicar-
bonate vs. 0.1% formic acid as the reconstitution buffer
in the negative mode, two sets of plasma samples were
deproteinized and lyophilized as aforementioned. One
set was reconstituted in 0.1% formic acid, whereas the
other in 6.5 mM ammonium bicarbonate, both of which
were then subjected to mass spectrometric analysis in
the negative mode. As illustrated in Figure 4, 0.1% for-
mic acid yielded greater signal than ammonium bicar-
bonate (2.29E4 vs. 3.49E3, respectively). Specifically,
this led to the detection of an additional 108 metabolite
peaks. Therefore, 0.1% formic acid was chosen as the re-
constitution solvent.
Adapting the workflow we devised, we were able
to retrieve most of our targeted metabolites, except L-
lysine, uric acid, and citric acid. This result may be due
to the signal suppression occurred during the direct in-
fusion, which could be circumvented by the incorpor-
ation of liquid chromatographic fractionation prior to
mass spectrometric analysis.
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In summary, an optimized sample preparation and work-
flow for targeted human plasma metabolites has been de-
vised and outlined in Figure 5. This newly developed
platform offers a simple albeit effective way to extract
most (13 out of 19) of our targeted metabolites. This
workflow in conjunction with LC-MS/MS will enable us
to establish a high throughput metabolomic platform to
characterize and validate these targeted metabolites as po-
tential biomarker in human heart failure.
Methods
Chemicals
Methanol, ethanol, chloroform, and water were purchased
from J.T. Baker (New Jersey, USA). Formic acid and am-
monium bicarbonate were from Sigma (St. Louis, USA).
Sample preparation for human plasma metabolites
Human whole blood was purchased from Biological Spe-
cialty Corporation (Colmar, USA). The whole blood was
first diluted with PBS in 1:1, followed by a 30 minute-
centrifugation at 700 g at room temperature. Plasma at
the top layer was then obtained.
Monophasic and biphasic deproteinizations of plasma
were depicted in Figure 2a and b. In brief, in the step of
monophasic deproteinization, various combinations of
methanol/ethanol (100%/0%; 80%/20%; 50%/50%; 20%/
80%; and 0%/100%) were added to 100 μL of plasma at a
ratio of either 1:3 or 1:9 (plasma:solvent). Subsequently,
sample was vortexed for 1-minute and incubated on ice for
20 minutes. After centrifugation at 20,000 g for 10 minutes
at 4°C, the supernatant was lyophilized at 45°C for 2 hours.
In the step of biphasic deproteinization, 200 μL of plasma
was mixed with 100 μL of chloroform and 200 μL of
methanol or ethanol. After which, it was vortexed for 1 mi-
nute. 200 μL of water and 200 μL of chloroform were then
added. After 1 minute of vortexing and 20 minutes of cen-
trifugation at 20,000 g at 4°C, hydrophilic and hydrophobic
metabolites at the top and bottom layers, respectively, were
collected and lyophilized at 45°C for 2 hours. The lyophi-
lized pellets as result were either reconstituted in equal ini-
tial plasma volume of 0.1% formic acid/H2O or 6.5 mM
ammonium bicarbonate/H2O prior to mass spectrometric
analysis.
Mass spectra acquisition
20 μL of the reconstituted metabolite extract was loaded
onto a nanoelectrospray tip (New Objective, Woburn,
USA), and subjected to Thermo Scientific LTQ orbitrap XL
hybrid FTMS for mass spectra acquisition. For ionization
source parameters, capillary temperature was set at 275°C;
while source and tube lens voltages were set at +/−2.2 kV
and +/−130 V, respectively. FT full MS scan was acquired
at 30,000 resolution with m/z range of 50–400 Th; whereaslinear ion trap (LIT) MS/MS scan was obtained via collision
induced dissociation (CID) with a normal m/z range of 50–
400 Th; isolation width of 1 Th; and normalized collision
energy of 35. All mass spectra were acquired in both posi-
tive and negative modes.
Metabolite identification
All MS/MS spectra were searched against the Human
Metabolome Database [49]. The search parameters were
set as follow: parent ion mass tolerance, ±0.01; fragment
ion m/z tolerance, ±0.1; CID energy, all. The outcome of
this putative identification was further validated by the
fragmentation pattern of the respective standards of the
same set of metabolites (Additional file 3).Additional files
Additional file 1: Summary notes: This file summarized the
identifications of targeted human plasma metabolites in the following
deproteinization conditions: (1) Monophasic deproteinization using
plasma: methanol (1:3); (2) monophasic deproteinization using plasma:
ethanol (1:3); (3) monophasic deproteinization using plasma: methanol
(1:9); (4) monophasic deproteinization using plasma: ethanol (1:9);
(5) biphasic deproteinization using methanol and chloroform; and
(6) biphasic deproteinization using ethanol and chloroform.
Additional file 2: Summary notes: This file summarized the
identifications of targeted human plasma metabolites in the
following monophasic deproteinization conditions: (1) Plasma:
methanol (1:3); (2) plasma: 80% methanol/ethanol (1:3); (3) plasma:
50% methanol/ethanol (1:3); (4) plasma: 20% methanol/ethanol
(1:3); (5) plasma: ethanol (1:3); (6) plasma: methanol (1:9);
(7) plasma: 80% methanol/ethanol (1:9); (8) plasma: 50% methanol/
ethanol (1:9); (9) plasma: 20% methanol/ethanol (1:9); and (10)
plasma: ethanol (1:9).
Additional file 3: Summary notes: This file illustrated the MS/MS
spectra acquired from the human plasma metabolites extracted
via the monophasic deproteinization using 20% methanol/ethanol.
The outcome of these putative identifications were further validated by
the fragmentation pattern of the respective standards of the same set
of metabolites.Abbreviations
CID: Collision induced dissociation; FTMS: Fourier transform mass
spectrometer; LC-MS/MS: Liquid chromatography-tandem mass
spectrometry; LIT: Linear ion trap.
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